ATC Group: L02BG Aromatase inhibitors

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L02BG in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L02 Endocrine therapy
3 L02B Hormone antagonists and related agents
4 L02BG Aromatase inhibitors

Group L02BG contents

Code Title
L02BG01 Aminogluthetimide
L02BG02 Formestane
L02BG03 Anastrozole
L02BG04 Letrozole
L02BG05 Vorozole
L02BG06 Exemestane

Active ingredients in L02BG

Active Ingredient Description
Anastrozole

Anastrozole is a potent and highly selective non-steroidal aromatase inhibitor. It inhibits the enzyme aromatase, which is responsible for converting androgens to estrogens. Anastrozole is a drug indicated in the treatment of breast cancer in post-menopausal women.

Exemestane

Exemestane is an irreversible, steroidal aromatase inhibitor, structurally related to the natural substrate androstenedione.

Formestane
Letrozole

Letrozole is a non-steroidal aromatase inhibitor. It inhibits the aromatase enzyme by competitively binding to the haem of the aromatase cytochrome P450, resulting in a reduction of oestrogen biosynthesis in all tissues where present.

Related product monographs

Title Information Source Document Type  
AREMED Film-coated tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
ARIMIDEX Film-coated tablets Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
AROMASIN Coated tablets Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
FEMARA Film-coated tablet Health Products Regulatory Authority (IE) MPI, EU: SmPC
LETROLE Film-coated tablet Medicines and Medical Devices Safety Authority (NZ) MPI, EU: SmPC
SADERON Film-coated tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC